KIT and plexiform neurofibroma: However, imatinib mesylate, an oral kinase inhibitor targeting c-kit and PDGFRβ, was recently reported to decrease plexiform neurofibromas by 20% or more in 6 out of 36 NF1 patients in a phase 2 trial.